2022
Cardiac Status Among Heart Failure Patients With Implantable Cardioverter Defibrillators Before, During, and After COVID-19 Lockdown
Lu Y, Jones PW, Murugiah K, Caraballo C, Mahajan S, Massey D, Ahmed R, Bader E, Krumholz H. Cardiac Status Among Heart Failure Patients With Implantable Cardioverter Defibrillators Before, During, and After COVID-19 Lockdown. Journal Of Cardiac Failure 2022, 28: 1372-1374. PMID: 35690314, PMCID: PMC9187866, DOI: 10.1016/j.cardfail.2022.05.012.Peer-Reviewed Original ResearchConceptsImplantable cardioverter defibrillatorHeart failure patientsCRT-D devicesCardiac statusFailure patientsHeart failureCardioverter defibrillatorCardiac resynchronization therapy defibrillatorAcute cardiac conditionsMedical care deliveryInpatient careCardiac conditionsPhysiologic markersInpatient servicesPatientsCardiac healthCare deliveryMarked restrictionImplanted ICDsMinneapolis/Saint PaulSex subgroupsDefibrillatorCOVID-19Telemedicine servicesCOVID-19 lockdown
2020
Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study
Mahajan S, Srinivasan R, Redlich CA, Huston SK, Anastasio KM, Cashman L, Massey DS, Dugan A, Witters D, Marlar J, Li SX, Lin Z, Hodge D, Chattopadhyay M, Adams MD, Lee C, Rao LV, Stewart C, Kuppusamy K, Ko AI, Krumholz HM. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study. The American Journal Of Medicine 2020, 134: 526-534.e11. PMID: 33130124, PMCID: PMC7598362, DOI: 10.1016/j.amjmed.2020.09.024.Peer-Reviewed Original ResearchConceptsSARS-CoV-2-specific IgG antibodiesWeighted seroprevalenceIgG antibodiesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodiesSARS-CoV-2-specific antibodiesConnecticut residentsSelf-reported adherenceImmunoglobulin G antibodiesSARS-CoV-2Symptomatic illnessSerology testingSeroprevalence studyG antibodiesPrevalence studyGeneral populationPercentage of peopleSeroprevalenceLack antibodiesMajority of respondentsAntibodiesHispanic subpopulationsConvenience sampleHispanic populationCOVID-19Risk mitigation behaviorsExtrapulmonary manifestations of COVID-19
Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia N, Ausiello JC, Wan EY, Freedberg DE, Kirtane AJ, Parikh SA, Maurer MS, Nordvig AS, Accili D, Bathon JM, Mohan S, Bauer KA, Leon MB, Krumholz HM, Uriel N, Mehra MR, Elkind MSV, Stone GW, Schwartz A, Ho DD, Bilezikian JP, Landry DW. Extrapulmonary manifestations of COVID-19. Nature Medicine 2020, 26: 1017-1032. PMID: 32651579, DOI: 10.1038/s41591-020-0968-3.Peer-Reviewed Original ResearchConceptsExtrapulmonary manifestationsCOVID-19Acute kidney injuryAcute coronary syndromeSpectrum of manifestationsCoronavirus SARS-CoV-2SARS-CoV-2Coronary syndromeGastrointestinal symptomsKidney injuryOcular symptomsThrombotic complicationsHepatocellular injuryEndothelial damageMyocardial dysfunctionDermatologic complicationsNeurologic illnessRespiratory pathologyImmune responseExtrapulmonary tissuesTherapeutic strategiesEntry receptorTissue damageOrgan systemsInjury